CuraGen to stop development of oral mucositis drug candidate

Oct 11 (Reuters) - CuraGen Corp CRGN.O, a biopharmaceutical company focused on oncology, said it would discontinue the development of its oral mucositis drug candidate, velafermin, after it failed to meet its main goal in a mid-stage trial.

The company said it would now continue to focus on belinostat, its drug candidate used to treat solid tumors and hematologic malignancies. (Reporting by Bijoy Koyitty in Bangalore)